CDT Equity (NASDAQ:CDT) Shares to Reverse Split on Tuesday, September 29th

by · The Markets Daily

CDT Equity Inc. (NASDAQ:CDT – Free Report) shares are going to reverse split on the morning of Tuesday, September 29th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 28th.

CDT Equity Price Performance

CDT traded down $0.04 on Friday, reaching $0.08. The company’s stock had a trading volume of 25,908,804 shares, compared to its average volume of 1,132,005. The stock has a market cap of $63,200.00, a price-to-earnings ratio of -0.00 and a beta of 1.48. CDT Equity has a 1 year low of $0.08 and a 1 year high of $1,778.00. The business’s 50 day moving average is $1.93 and its 200 day moving average is $24.26.

CDT Equity (NASDAQ:CDT – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($8.71) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a report on Monday. Wall Street Zen raised shares of CDT Equity from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CDT Equity currently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on CDT Equity

CDT Equity Company Profile

(Get Free Report)

CDT Equity, Inc, traded on the Nasdaq under the symbol CDT, is associated with Conduit Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune and inflammatory diseases.

The company’s business model centers on acquiring and advancing clinical-stage drug candidates through partnerships with academic institutions and pharmaceutical companies. Its portfolio has included investigational therapies intended to address conditions such as systemic sclerosis and other immune-mediated diseases, although the status and composition of its development programs may change as clinical and corporate activities progress.

Conduit Pharmaceuticals was established to help translate externally developed drug candidates into commercial medicines.

Featured Articles